Genomics and proteomics: Role in the management of multiple sclerosis

Journal of Neurology

Volumn 252, Issue SUPPL. 3, 2005, Pages

  Kappos, Ludwig ^a   Achtnichts, Lutz ^a   Dahlke, Frank ^b   Kuhle, Jens ^a   Naegelin, Y ^a   Sandbrink, Rupert ^b   Lindberg, Raija L P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BAYER PHARMA AG   (Germany)

Author keywords

Genomics; Interferon beta 1b; Multiple sclerosis; Pharmacogenetics; Proteomics

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; RNA;

BIOTECHNOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; DNA MICROARRAY; DOSE TIME EFFECT RELATION; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC DIFFERENCE; GENETIC IDENTIFICATION; GENETIC MARKER; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; IMMUNOPATHOLOGY; MULTIPLE SCLEROSIS; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENOMICS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROTEOMICS;

EID: 25144475936     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-2013-3     Document Type: Conference Paper

References (48)

1. Barkhof F, Filippi M, Comi G, the ETOMS Study Group (2002) Diagnostic MRI Criteria: Prediction of Conversion to CDMS. AAN 2002, Denver, USA. Neurology 58(Suppl 3):S157
2. Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51:481-490
3. Becker KG, Mattson DH, Powers JM, Gado AM, Biddison WE (1997) Analysis of a sequenced cDNA library from multiple sclerosis lesions. J Immunol 77:27-38
4. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Eng J Med 349:139-145
5. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14:271-278
6. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM (2003) Gene expression profile in multiple sclerosis patients and healthy controls to disease. Hum Mol Genet 12:2191-2199
7. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Eng J Med 346:158-164
8. Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rudel R (2000) An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med 6:808-811
9. Butte A (2002) The use and analysis of microarray data. Nat Rev Drug Discov 1:951-960
10. Celis JE, Gromov P (2003) Proteomics in translational cancer research: towards an integrated approach. Cancer Cell 3:9-15
11. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735
12. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR, Early Treatment of Multiple Sclerosis Study Group (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576-1582
13. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58:65-70
14. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM (1999) Expression profiling using cDNA microarrays. Nat Genet 21(Suppl 1):10-14
15. Dumont D, Noben J-P, Raus J, Stinissen P, Robben J (2004) Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 4:2117-2124
16. Dyment DA, Ebers GC (2002) An array of sunshine in multiple sclerosis. N Eng J Med 347:1445-1447
17. Freedman M, Edan G, Hartung HP, Kappos L, Miller D, Montalban X, Polman C, Barkhof F, Bauer L, Ghazi M, Sandbrink R (2003) Betaferon®/Betaseron® (Interferon beta-1b) in early treatment of multiple sclerosis: the Benefit study. Neurology 60(Suppl 1):A483
18. Graham KL, Robinson WH, Steinman L, Utz PJ (2004) High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. Autoimmunity 37:269-272
19. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13:554-573
20. Grekova MC, Robinson ED, Faerber MA, Katz P, McFarland HF, Richert JR (1996) Deficient expression in multiple sclerosis of the inhibitory transcription factor Sp3 in mononuclear blood cells. Ann Neurol 40:1080-1112
21. Hammack BN, Owens GP, Burgoon MP, Gilden DH (2003) Improved resolution of human cerebrospinal fluid proteins on two-dimensional gels. Mult Scler 9:472-475
22. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ (2004) Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 152:126-139
23. Hueber W, Utz PJ, Steinman L, Robinson WH (2002) Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 4:290-295
24. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Eng J Med 343:898-904
25. Juan HF, Chen JH, Hsu WT, Huang SC, Chen ST, Yi-Chung Lin J, Chang YW, Chiang CY, Wen LL, Chan DC, Liu YC, Chen YJ (2004) Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 4:2766-2775
26. Kappos L, Achtnichts L, Durelli L, Fernandez O, Petereit H, De Sa J, Siva A, Radue EW, Daumer M, for the BEST-PGx Study Group (2004) BEST-PGx: design of a pharmacogenomic and pharmacogenetic study to identify criteria for prediction of treatment response to interferon beta-1b. Mult Scler 10(Suppl 2):S245
27. Kinkel R, on behalf of the CHAMPS Study Group (2002) The effect of Avonex® in patients with a single demyelinating event and MRI evidence of high lesion burden and active inflammation. ENS, Berlin, Germany
28. Koike F, Satoh J, Miyake S, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Kanda T, Fukazawa T, Yamamura T (2003) Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol 139:109-118
29. Leung YF, Cavalieri D (2003) Fundamentals of cDNA microarray data analysis. Trends Genet 19:649-659
30. Lindberg RLP, DeGroot CJA, Certa U, Ravid R, Hoffmann F, Kappos L, Leppert D (2004) Multiple sclerosis as a generalized CNS disease-comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J Neuroimmunol 152:154-167
31. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, Petricoin EF (2003) Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3:317-325
32. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500-508
33. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
34. Martin R, Sturzebecher CS, McFarland HF (2001) Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat Immunol 2:785-788
35. Mycko MP, Papoian R, Boschert U, Raine CS, Selmaj KW (2003) cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 126:1048-1057
36. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
37. Ramanathan M, Weinstock-Guttman B, Nguyen LT, Badgett D, Miller C, Patrick K, Brownscheidle C, Jacobs L (2001) In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol 116:213-219
38. Robinson WH, Steinman L, Utz PJ (2003) Proteinarrays for autoantibody profiling and fine-specificity mapping. Proteomics 3:2077-2084
39. Schulze A, Downward J (2001) Navigating gene expression using microarrays - a technology review. Nat Cell Biol 3:E190-E195
40. rd, Brownscheidle CM (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 53:139-148
41. Smolen P, Baxter DA, Byrne JH (2000) Mathematical modeling of gene networks. Neuron 26:567-580
42. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126:1419-1429
43. Surrogate Markers of Clinical Disease in Multiple Sclerosis (2002) Proceedings of the MS Forum Modern Management Workshop. PAREXEL MMS Europe Ltd, Worthing, UK, p 32
44. Tajouri L, Mellick AS, Ashton KJ, Tannenberg AEG, Nagra RM, Tourtelotte WW, Griffiths LR (2003) Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Mol Brain Res 119:170-183
45. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Eng J Med 338:278-285
46. Wandinger KP, Sturzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R (2001) Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 50:349-357
47. Whitney LW, Becker KG, Tresser NJ, Caballero-Ramos CI, Munson PJ, Prabhu VV, Trent JM, McFarland HF, Biddison WE (1999) Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann Neurol 46:425-428
48. Whitney LW, Ludwin SK, McFarland HF, Biddison WE (2001) Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Immunol 121:40-48